Clinical trials: Oropharyngeal Cancers
Cancer T1-N0 or T2-N0 of the Oral Cavity
Sentinel. Ambulatory. Oral Cavity. Oropharynx (S.A.C.O)
This is a single-center pilot study of open-label, non-randomized interventional research based on the outpatient management of 30 patients with T1-N0 or T2-N0 cancer in the oral cavity or oropharynx.
- Trial name
- SACO (NCT03545256)
- Testing
- outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Squamous Cell Carcinoma of the Oral Cavity, Oropharynx Metastases
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
In this study, the feasibility of optical imaging and FDG-PET in the evaluation of radiation-induced mucositis will be evaluated.
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Oropharynx Metastases, Lymph Metastases
- Trial name
- NCT01077869
- Testing
- endoscopic examination, FDG-PET
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Ghent
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Some cancers may be related to an infection with a virus, such as the Human Papilloma Virus (HPV). HPV related Oropharyngeal cancer (HPVOPC) accounts for 80% of oropharynx cancer cases in the United States.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02002182
- Testing
- ADXS11-001 (ADXS-HPV)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Sikora
Head and Neck Cancer
Biomarkers in Patients With Head and Neck Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.
- Trial name
- NCT01466257
- Testing
- cetuximab, cisplatin, DNA analysis
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Head and Neck Tumors
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
Currently, patients with cancer of oral cavity or oropharynx T1-T2N0 classified, are treated surgically with systematic lymph node dissection while in 70%, there is no lymph node metastasis.
- Trial name
- SentiMERORL (NCT02855723)
- Testing
- Surgery: GS strategy, Surgery: Classic strategy
- Where
- France
- Volunteers
- 307 people
- Sponsor
- University Hospital, Montpellier
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
- Trial name
- NCT03237325
- Testing
- SGX942
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 266 people
- Sponsor
- Soligenix
Head and Neck Cancer
Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy
It is currently estimated that above 50% of new cancer cases are diagnosed in the elderly population[1]. With the increased life expectancy in the industrialised countries, the incidence of head and neck cancers has significantly…
- Trial name
- NCT01709006
- Testing
- Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Head and Neck Cancer
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- DORA (NCT01313390)
- Testing
- docetaxel, everolimus, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck.
- Conditions
- Oropharyngeal Neoplasms, Robotic Surgery and/or Radiotherapy, Lymphoscintigraphy
- Trial name
- NCT06167291
- Testing
- Arm 1- Ipsilateral
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Radiation-Induced Oral Mucositis (RTOM), Head and Neck Cancer
Sancai Fengsui Decoction for RTOM: A Multicenter RCT
How to promote the prognosis and outcome of RTOM, restore oral function, and improve quality of life are key issues for improving the long-term outcomes of head and neck malignant tumor radiotherapy, and are also integral parts…
- Conditions
- Radiation-Induced Oral Mucositis (RTOM), Head and Neck Cancer, Oral Mucositis of RTOG Grade Greater Than 1
- Trial name
- NCT07692997
- Testing
- Sancai Fengsui Decoction
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
This phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT07156227
- Testing
- Biospecimen Collection, Camonsertib, Computed Tomography
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or…
- Trial name
- NCT00003327
- Testing
- paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 60 people
- Sponsor
- Theradex
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Previous studies confirmed locally advanced oral/oropharyngeal squamous cell carcinoma (LA OSCC or OPSCC) patients with a pathological response had higher probability of survival in neoadjuvant settings.
- Trial name
- NCT06009861
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- Peking University Hospital of Stomatology
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival…
- Trial name
- NCT07513324
- Testing
- Pembroluzimab, Observation
- Sponsor
- Dana-Farber Cancer Institute
Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy
This phase I trial studies the side effects and best dose of entolimod in treating patients with stage III-IV or recurrent head and neck cancer.
- Conditions
- Mucositis, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01728480
- Testing
- entolimod, intensity-modulated radiation therapy, cisplatin
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer, Oropharyngeal Cancer
Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
To evaluate the use of the daVinci Robotic System for better visibility and access of head and neck lesions and decreased amount of surgery time.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer, Upper Aerodigestive Tract Neoplasms
- Trial name
- NCT00473564
- Testing
- da Vinci® Robotic System
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Alabama at Birmingham
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Head and Neck Cancer
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
- Trial name
- NCT00900419
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- University of Colorado, Denver